SBPH Spring Bank Pharmaceuticals Inc.

4.73
-0.05  -1%
Previous Close 4.78
Open 4.78
Price To Book 1.51
Market Cap 77,776,014
Shares 16,443,132
Volume 19,654
Short Ratio
Av. Daily Volume 101,963

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at EASL April 12, 2019.
Inarigivir and Vemlidy - ACHIEVE
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)
IND submission announced July 1, 2019. Phase 1 data due mid-2020.
SB 11285
Solid tumors
Phase 2 initial data due 2H 2019.
Inarigivir and NUCs
Hepatitis B (HBV)
Phase 2b top-line data due 2020 and 2021.
Inarigivir - (CATALYST 1 and CATALYST 2)
Hepatitis B (HBV)

Latest News

  1. Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
  2. Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
  3. Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
  4. Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
  5. Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
  6. Did Changing Sentiment Drive Spring Bank Pharmaceuticals's (NASDAQ:SBPH) Share Price Down By 50%?
  7. Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
  8. Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
  9. Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
  10. Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
  11. Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
  12. Edited Transcript of SBPH earnings conference call or presentation 11-Mar-19 12:00pm GMT
  13. Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
  14. Spring Bank Pharmaceuticals, Inc. to Host Earnings Call
  15. Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
  16. Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
  17. Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
  18. Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
  19. Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
  20. Spring Bank Announces Additional Inarigivir Results at AASLD Conference